All sponsors

Telix Pharmaceuticals (Innovations) Pty Limited

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-36
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO60%

Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +7.0 months). See all sponsors →

Open Telix Pharmaceuticals (Innovations) Pty Limited on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
89Zr-TLX250 PET/CT
NCT06750419
P3RecruitingClear Cell Renal Cell Carcinoma822026-06-30
BiPASS
NCT07052214
P3Active, not recruitingPCA; Prostate Cancer3382027-01 (+7 mo)
LUTEON
NCT07197580
P3RecruitingccRCC; Renal Cell Carcinoma (Kidney Cancer)402027-08-31 (+8 mo)
177Lu-TLX591
NCT06520345
P3RecruitingMetastatic Castration-resistant Prostate Cancer5202027-12
TLX101-Px
NCT07931261
P3Not yet recruitingBrain Metastasis; Radiation Necrosis3812028-04
IPAX BrIGHT
NCT07100730
P3RecruitingNeoplastic Disease; Glioblastoma512028-07 (+12 mo)
LUTEON ATLAS
NCT07870746
P2Not yet recruitingccRCC; Renal Cell Carcinoma (Kidney Cancer)402028-12-31